A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

NCT07526974 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Subcutaneous Fat

Interventions

DRUG: CBL-514 Injection
DRUG: 0.9% Sodium Chloride

Sponsor

Caliway Biopharmaceuticals Co., Ltd.